Comparing the Effect of Vaginal Misoprostol With Dinoprostone in Term Pregnancies
Information source: Hormozgan University of Medical Sciences
ClinicalTrials.gov processed this data on November 27, 2014
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Preeclampsia; Fetal Death; Fetal Membranes, Premature Rupture
Intervention: misoprostol (Drug); dinoprostone (Drug)
Phase: Phase 1/Phase 2
Status: Not yet recruiting
Sponsored by: Hormozgan University of Medical Sciences
Official(s) and/or principal investigator(s):
Mitra Ahmad Soltani, Principal Investigator, Affiliation: Hormozgan University of Medical Sciences
Minoo Rajaee Lari, Perinatologist - Obs and Gyn, Study Chair, Affiliation: Department of Obs and Gyn - HUMS
Hypothesis (H0): Labor duration and obstetric complications are not significantly different
in the three groups (misoprostol-dinoprostone-oxytocin).
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Minimum age: N/A.
Maximum age: N/A.
- Term pregnancy
- Bishop score below 6
- History of drug reaction
- Medical disease
- Vaginal bleeding
- Fetal anomaly
- Uterine scar
Locations and Contacts
Shariaty Maternity Hospital, Tehran, Iran, Islamic Republic of; Not yet recruiting
Mitra Ahmad Soltani, MD, Phone: 0098 021 22301004, Email: firstname.lastname@example.org
Last updated: May 31, 2007